Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Avi Kapoor
Insiders are buying shares of Monopar Therapeutics, Brookmount Explorations, and Nexalin Technology, indicating confidence in these companies. Monopar's COO bought shares following a collaboration extension, Brookmount's CEO acquired shares after strong sales, and Nexalin's CMO purchased shares following a patent announcement.
June 24, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Brookmount Explorations' CEO Nils Ollquist acquired 3,343,210 shares at $0.13 each, following strong first-quarter sales.
The large insider purchase by the CEO indicates strong confidence in the company's performance, especially after reporting strong first-quarter sales. This is likely to positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Monopar Therapeutics' COO Andrew Cittadine bought 32,508 shares at $0.79 each, following an amendment and extension to their collaboration with NorthStar.
The insider purchase by the COO suggests strong confidence in the company's future, especially following a significant collaboration extension. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Nexalin Technology's CMO David Owens acquired 1,619 shares at $0.71 each, following a patent announcement for a new neurostimulation device.
The insider purchase by the CMO following a significant patent announcement suggests confidence in the company's innovative products. This is likely to positively impact the stock price in the short term.
CONFIDENCE 88
IMPORTANCE 75
RELEVANCE 100